SPRY2 and hepatocellular carcinoma: The potential tumor suppressive role of Spry2 in HCC was investigated by expressing a dominant negative form of Spry2 (Spry2Y55F) and an activated β-catenin in mouse liver through hydrodynamic injection and the SB transposon system.